BioSpace News Archive

Premier CBRNE training facility uses 908 Devices MX908 portable mass spec devices for trace detection of hazardous chemicals.

IMV Inc. announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022.

BiondVax today announced the signing of definitive agreements with the Max Planck Society (MPG) and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies (NanoAbs*).

TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations.

- DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales and Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States.

Allarity Therapeutics, Inc. today announced the submission of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) seeking marketing approval for dovitinib for the third-line treatment of renal cell carcinoma (RCC) patients.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.

Outlook Therapeutics, Inc. today announced recent corporate highlights and financial results for its fiscal year ended September 30, 2021.

Novadoz Pharmaceuticals is excited to announce that their corporate group entity, MSN Pharmaceuticals, has cleared USFDA audit with zero observations for their new, state-of-the-art, 200,000 sq. ft. manufacturing facility in Piscataway, NJ.

Agenus (NASDAQ: AGEN), today announced the publication of results in the Journal of Clinical Oncology (JCO) from a global Phase 2 clinical study of balstilimab (Bal) plus zalifrelimab (Zal) in second-line (2L) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy.